Differences between long-acting insulins for the treatment of type 2 diabetes

Bibliography

• International Diabetes Federation [internet]. Brussels. The Federation c1950-2009. Available from: http: www.idf.org/diabetes-prevalence. 2009. [Cited 5 October 2009]
   Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• Nathan DM, Zinman B, Cleary PA, Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009;169:1307-16
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Miller ME, Bonds DE, Gerstein HC, The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010;340:b5444
   PubMed Web of Science ®Google Scholar
• Ray KK, Seshasai SR, Wijesuriya S, Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-72
   PubMed Web of Science ®Google Scholar
• Finfer S, Chittock DR, Su SY, Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-97
   PubMed Web of Science ®Google Scholar
• Rungby J, Krentz A. Pharmacotherapy of diabetes–New developments. Springer Verlag; 2007
   Google Scholar
• Heise T, Nosek L, Ronn BB, Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614-20
   PubMed Web of Science ®Google Scholar
• Rungby J, Brock B, Schmitz O. New strategies in insulin treatment: analogues and noninvasive routes of administration. Fundam Clin Pharmacol 2005;19:127-32
   PubMedGoogle Scholar
• European Medicine Agencies (EMEA) [internet]. London: the Agency; c1995-2009. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/levemir/093604en6.pdf. 2009. [Cited 5 September 2009]
   Google Scholar
• Sørensen L P, Brock B, Mengel A, Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24 hours euglycemic clamp studies in healthy humans. Diabet Med 2010; in press
   PubMedGoogle Scholar
• Sorensen LP, Djurhuus CB, Brock B, No evidence for essential differences between the effects of insulin glargine, detemir and NPH on glucose homeostasis after a single injection as assessed by 24-h euglycemic clamp studies in healthy humans. Diabetes 2006;55:A135
   Google Scholar
• Horvath K, Jeitler K, Berghold A, Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;18(2):CD005613
   Google Scholar
• Thisted H, Johnsen SP, Rungby J. An update on the long-acting insulin analogue glargine. Basic Clin Pharmacol Toxicol 2006;99:1-11
   PubMedGoogle Scholar
• Donnelly LA, Morris AD, Evans JM. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM 2007;100:345-50
   PubMed Web of Science ®Google Scholar
• Hollander P, Cooper J, Bregnhoj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008;30:1976-87
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Davies M, Home PD, A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-16
   PubMed Web of Science ®Google Scholar
• Eliaschewitz FG, Calvo C, Valbuena H, Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res 2006;37:495-501
   PubMed Web of Science ®Google Scholar
• Massi BM, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003;35:189-96
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Schwartz SL, Clark CM Jr, Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-6
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-6
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-51
   PubMed Web of Science ®Google Scholar
• Fajardo MC, Hernandez HC, Rivas FM. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabet Med 2008;25:916-23
   PubMedGoogle Scholar
• Haak T, Tiengo A, Draeger E, Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005;7:56-64
   PubMed Web of Science ®Google Scholar
• Hermansen K, Davies M, Derezinski T, A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-74
   PubMed Web of Science ®Google Scholar
• Philis-Tsimikas A, Charpentier G, Clauson P, Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-81
   PubMed Web of Science ®Google Scholar
• Raslova K, Bogoev M, Raz I, Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193-201
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• Chow CC, Tsang LW, Sorensen JP, Cockram CS. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 1995;18:307-14
   PubMed Web of Science ®Google Scholar
• Taylor R, Davies R, Fox C, Appropriate insulin regimes for type 2 diabetes: a multicenter randomized crossover study. Diabetes Care 2000;23:1612-8
   PubMedGoogle Scholar
• Kolendorf K, Ross GP, Pavlic-Renar I, Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet Med 2006;23:729-35
   PubMed Web of Science ®Google Scholar
• Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ 2007;33:1014-29
   PubMed Web of Science ®Google Scholar
• Pieber TR, Treichel HC, Hompesch B, Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med 2007;24:635-42
   PubMed Web of Science ®Google Scholar
• Gin H, Hanaire-Broutin H. Reproducibility and variability in the action of injected insulin. Diabetes Metab 2005;31:7-13
   PubMed Web of Science ®Google Scholar
• Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med 2005;118(Suppl 5A):27S-34S
   PubMedGoogle Scholar
• Home P, Bartley P, Russell-Jones D, Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004;27:1081-7
   PubMed Web of Science ®Google Scholar
• Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev 2005;21:545-53
   PubMed Web of Science ®Google Scholar
• Raskin P, Klaff L, Bergenstal R, A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000;23:1666-71
   PubMed Web of Science ®Google Scholar
• Esposito K, Ciotola M, Maiorino MI, Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 2008;149:531-9
   PubMed Web of Science ®Google Scholar
• Swinnen SG, Dain MP, Aronson R, A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 2010;33(6):1176-8
   Google Scholar